Eli Lilly Alzheimer's Drug Delayed as FDA Plans Advisory Panel Meeting
The timing of the agency’s expected action on the donanemab drug would be postponed beyond the first quarter, the company said.
The timing of the agency’s expected action on the donanemab drug would be postponed beyond the first quarter, the company said.
FOLLOW US ON GOOGLE NEWS
Read original article here
Denial of responsibility! Techno Blender is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful…